Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Sarcoma Res
Hlavní autoři: Gaston, Czar Louie, Grimer, Robert J., Parry, Michael, Stacchiotti, Silvia, Dei Tos, Angelo Paolo, Gelderblom, Hans, Ferrari, Stefano, Baldi, Giacomo G., Jones, Robin L., Chawla, Sant, Casali, Paolo, LeCesne, Axel, Blay, Jean-Yves, Dijkstra, Sander P. D., Thomas, David M., Rutkowski, Piotr
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5022265/
https://ncbi.nlm.nih.gov/pubmed/27651889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-016-0056-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky